Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01277081
Other study ID # C7100991
Secondary ID
Status Completed
Phase Phase 2
First received January 12, 2011
Last updated February 2, 2015
Start date October 2010
Est. completion date December 2010

Study information

Verified date June 2013
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

The aim of this study is to subjectively assess symptoms in subjects suffering from the common cold following a single dose of paracetamol hot drink compared to paracetamol tablet


Recruitment information / eligibility

Status Completed
Enrollment 200
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Symptoms of the common cold of no more than 120 hours duration

- Self-rating congestion of at least moderate severity

- Suffering from at least four symptoms of common cold or flu

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Drug:
Paracetamol hot drink
Hot drink containing paracetamol
Paracetamol tablets
Paracetamol tablets

Locations

Country Name City State
United Kingdom Common Cold Centre Cardiff Wales

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Breathing Scores Post 15 Minutes A mean breathing score was calculated at baseline, 30 seconds, 2, 5 and 15 minutes, derived from participant responses to questions relating to breathing i.e. "my breathing feels easy", "I feel airways are open", "I feel a cooling sensation in my throat", "I can feel the air flowing to my lungs easily", "My nose feels less blocked" and "I feel my breathing is comfortable". The breathing scores were rated by the participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. For each participant, a mean score was derived by summing the responses and dividing by the number of questions answered. Baseline to 15 minutes No
Secondary Breathing Score Post 60 Minutes A mean breathing score was calculated at baseline, 30 seconds, 2, 5, 15 and 60 minutes, derived from participant responses to questions relating to breathing i.e. "my breathing feels easy", "I feel airways are open", "I feel a cooling sensation in my throat", "I can feel the air flowing to my lungs easily", "My nose feels less blocked" and "I feel my breathing is comfortable". The breathing scores were rated by the participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. For each participant, a mean score was derived by summing the responses and dividing by the number of questions answered. Baseline to 60 minutes No
Secondary Cold Symptoms Score Post 15 Minutes A mean Cold symptom score was calculated at baseline, 30 seconds, 2, 5 and 15 minutes from participant responses to questions relating to cold symptoms i.e. "My head feels clear", "I feel soothing in my throat" and "I feel my cough is being soothed". The cold symptom scores were rated by the participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. For each participant, a mean score was derived by summing the responses and dividing by the number of questions answered. Baseline to 15 minutes No
Secondary Cold Symptoms Score Post 60 Minutes A mean Cold symptom score was calculated at baseline, 30 seconds, 2, 5, 15 and 60 minutes from participant responses to questions relating to cold symptoms i.e. "My head feels clear", "I feel soothing in my throat" and "I feel my cough is being soothed". The cold symptom scores were rated by the participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. For each participant, a mean score was derived by summing the responses and dividing by the number of questions answered. Baseline to 60 minutes No
Secondary Soothing Attribute Scores Soothing attribute of test treatment was assessed by asking the question "if the hot drink is soothing" at baseline, 15 and 60 minutes. The response to the question was rated by participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. Baseline to 15 and 60 minutes No
Secondary Overall Cold Symptoms Score Overall cold symptom score was assessed by asking the question "my cold symptoms are improved" only post consuming the drink at baseline, 15 and 60 minutes . The response to the question was rated by participants on a 5 point (0-4) rating scale with '0' being labeled as 'strongly disagree' and '4' being labeled as 'strongly agree'. Baseline to 15 and 60 minutes No
See also
  Status Clinical Trial Phase
Completed NCT05269290 - Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections Phase 3
Completed NCT02451163 - DBRCT on the Effect of Wheat Polysaccharides on Common Cold Infections in Elderly Phase 2
Completed NCT01944631 - Iota-Carrageenan Nasal Spray in Common Cold Phase 4
Completed NCT01651715 - Efficacy and Safety Study of Homeopathic Oral Antibodies to Treat Viral Upper Respiratory Tract Infections Phase 1/Phase 2
Completed NCT00963443 - Acetylsalicylic Acid Combined With Pseudoephedrine in Common Cold Phase 3
Completed NCT00778648 - Encapsulated Juice Powder Concentrate for Preventing Common Cold Symptoms N/A
Completed NCT00065715 - Echinacea Versus Placebo Effect in Common Cold (Physician Echinacea Placebo) Phase 3
Completed NCT00032500 - Evaluation of Echinacea for the Common Cold Phase 2
Not yet recruiting NCT05070650 - Efficacy and Safety of the Combination of Acetylcysteine, Paracetamol and Phenylephrine for the Treatment of Common Cold Phase 3
Not yet recruiting NCT04073511 - Herbal Medicine 'Eungyosan' and 'Samsoeum' for Common Cold N/A
Completed NCT04144491 - Effect of L. Rhamnosus Yoba on RTI and Other Health Outcomes Among Children (3-6 Years) in Uganda N/A
Completed NCT03189537 - Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections Phase 3
Terminated NCT01964885 - Benefit and Tolerability of IQP-AS-105 in Reducing Susceptibility to Upper Respiratory Tract Infections Phase 3
Completed NCT01728090 - Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections Phase 4
Completed NCT00405509 - The Natural History of Viral Upper Respiratory Infections in Children Aged 6 to Less Than 14 Years N/A
Completed NCT01033526 - Symptomatic Treatment of Common Cold Symptoms Phase 4
Completed NCT05556148 - Otrivine: Quality of Life (QoL) Impact in a Real-World Setting Phase 4
Terminated NCT03339726 - Randomized, Double-blind, Placebo-Controlled, Efficacy Study of a New Formulation of Phenylephrine HCL in the Common Cold Phase 2
Completed NCT01361399 - Active and Placebo Controlled Study to Test the Efficacy and Safety of an Aspirin-Lidocaine Lozenge in the Symptomatic Treatment of Sore Throat Associated With a Common Cold Phase 3
Recruiting NCT05244148 - Two Seawater-based Formulations for Relief of Nasal Congestion in Paediatric Subjects N/A